Danny Barlev, MD
Dermatology · Cleveland, OHNPI 1285991372
Payments from drug & device makers
Across 33 payments — averaging $20.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$119
- Lilly USA, LLC$84
- Amgen$77
- Sanofi$74
- Johnson & Johnson$70
- Regeneron Healthcare Solutions, Inc.$49
- plus $198 from 8 others
What the payments were for
- Food & beverage$64696%
- Education$264%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 6 | $119 |
| Lilly USA, LLC | 5 | $84 |
| Amgen | 4 | $77 |
| Sanofi | 3 | $74 |
| Johnson & Johnson | 3 | $70 |
| Regeneron Healthcare Solutions, Inc. | 2 | $49 |
| Novartis | 2 | $43 |
| UCB, Inc. | 1 | $29 |
| Pfizer | 2 | $26 |
| Boehringer Ingelheim | 1 | $24 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Sun Pharmaceutical Industries Inc. | 1 | $19 |
| Arcutis Biotherapeutics, Inc. | 1 | $15 |
How this compares
$672 in reported general payments places this provider in the 25th percentile of 460 dermatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 51 | $395,055 |
| Humira(Cf) PenAdalimumab | 21 | $279,897 |
| Taltz AutoinjectorIxekizumab | 40 | $271,020 |
| Skyrizi PenRisankizumab-Rzaa | 12 | $251,956 |
| Dupixent PenDupilumab | 62 | $235,703 |
| Cosentyx Unoready PenSecukinumab | 12 | $141,170 |
| Dupixent SyringeDupilumab | 16 | $61,168 |
| Clobetasol Propionate | 134 | $5,810 |
| Tacrolimus | 29 | $5,566 |
| Fluocinonide | 77 | $4,169 |
| Clindamycin Phosphate | 81 | $3,270 |
| Ketoconazole | 172 | $2,867 |
| Tretinoin | 39 | $2,596 |
| Triamcinolone Acetonide | 123 | $2,241 |
| Metronidazole | 22 | $1,381 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Cleveland
- Neil KormanCleveland$6M
- Anthony FernandezCleveland$1.4M
- Wilma BergfeldCleveland$642K
- Shilpi KhetarpalCleveland$383K
- Edward MaytinCleveland$190K
- Alex HirshCleveland$159K
- Mara Weinstein VelezCleveland$129K
- Samantha PollyCleveland$80K
- Matthew ZirwasBexley$7.4M
- Jeffrey TraversDayton$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.